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The relaxin-3 neuropeptide activates the relaxin family pep-
tide 3 (RXFP3) receptor tomodulate stress, appetite, and cogni-
tion. RXFP3 shows promise as a target for treating neurological
disorders, but realization of its clinical potential requires devel-
opment of smaller RXFP3-specific drugs that can penetrate the
blood–brain barrier. Designing such drugs is challenging and
requires structural knowledge of agonist- and antagonist-bind-
ing modes. Here, we used structure–activity data for relaxin-3
and a peptide RXFP3 antagonist termed R3 B1–22R to guide
receptor mutagenesis and develop models of their binding
modes. RXFP3 residues were alanine-substituted individually
and in combination and tested in cell-based binding and func-
tional assays to refine models of agonist and antagonist binding
to active- and inactive-state homology models of RXFP3,
respectively. These models suggested that both agonists and
antagonists interact with RXFP3 via similar residues in their
B-chain central helix. The models further suggested that the
B-chain Trp27 inserts into the binding pocket of RXFP3 and
interacts with Trp138 and Lys271, the latter through a salt bridge
with the C-terminal carboxyl group of Trp27 in relaxin-3. R3
B1–22R, which does not contain Trp27, used a non-native Arg23
residue to form cation– and salt-bridge interactions with
Trp138 and Glu141 in RXFP3, explaining a key contribution of
Arg23 to affinity. Overall, relaxin-3 and R3 B1–22R appear to
share similar binding residues but may differ in binding modes,
leading to active and inactive RXFP3 conformational states,
respectively. These mechanistic insights may assist structure-
based drug design of smaller relaxin-3mimetics tomanage neu-
rological disorders.
Relaxin-3 is the most recently identified member of the
relaxin peptide family and is a neuropeptide highly expressed in
the brain. It was discovered in 2002 based on a search of the
human genome database (1), and subsequently homologs of the
relaxin-3 gene (RLN3) were found in other species, such as
mouse, rat, pig, frog, chimpanzee, and macaque, and orthologs
of relaxin-3 were found in fish, such as the Fugu (Takifugu
rubripes) and zebrafish (Danio rerio) (2). Relaxin family pep-
tides bind to class AGprotein–coupled receptors known as the
relaxin family peptide (RXFP)5 receptors (3). The relaxin family
peptides are part of the insulin peptide superfamily (4) and
share structural homology with two peptide chains, A and B,
cross-linked by three disulfide bonds: two interchain disulfide
bonds between the A- and B-chain and one intrachain disulfide
bond in the A-chain (4, 5). The endogenous receptor for relax-
in-3 is RXFP3 (6) and was previously known as GPCR135 or
somatostatin and angiotensin-like peptide receptor (SALPR)
(3, 6, 7). Relaxin-3 can also bind toRXFP1 (8) andRXFP4 (9, 10),
the endogenous receptors for relaxin-2 (also known as just
“relaxin”) and insulin-like peptide 5 (INSL5), respectively.
Relaxin-3 is highly expressed in the brains of all species
where the gene has been identified, including zebrafish (11),
mouse (1), rat (12),macaque (13, 14), andhumans (6). Extensive
studies inmice and rats have determinedhigh levels of relaxin-3
expression in the ventromedial dorsal tegmental area also
known as the nucleus incertus (NI) (1, 12, 15–17). Its high
expression and extensive overlap of relaxin-3–containing
fibers with the expression of RXFP3 in certain areas of the brain
suggests that relaxin-3 has distinct and important functional
roles (1, 17, 18). Indeed, relaxin-3 has been shown to be
involved in a wide range of behaviors, which include spatial
learning and memory (19); modulation of stress, mood, and
arousal (20, 21); feeding and appetite (22); and addiction (23).
The importance of the relaxin-3/RXFP3 system suggests that
its receptor is a highly relevant target for developing receptor-
specific drugs to treat neurological diseases.
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Numerous studies have been focused on understanding
structure activity relationship of relaxins (24). The relaxin-3
B-chain alone is capable of interacting with RXFP3, suggesting
that the A-chain of relaxin-3 is not crucial for RXFP3 interac-
tions (6, 25). Studies using a recombinant expression system to
generate chimeric peptides consisting of A-chains from other
relaxin family peptides together with the relaxin-3 B-chain
demonstrated that a peptide consisting of the INSL5 A-chain
and relaxin-3 B-chain (R3/I5) was a selective agonist for RXFP3
over RXFP1 (26). The NMR solution structures of native relax-
in-3 and this chimera revealed that the center of the B-chain
adopts a helical conformation (27, 28). The helix is important
for activity, and recently, Hojo et al. (29) and Jayakody et al. (30)
showed that hydrocarbon stapling on the B-chain of relaxin-3
can produce relaxin-3 single-chain analogs that retain potent
agonist activity. NMR analysis highlighted that the stapled pep-
tide mimicked the -helical structure of the relaxin-3 B-chain
(29) and further demonstrated that theB-chain is solely respon-
sible for binding and activation of RXFP3. These studies dem-
onstrate that the A-chain of relaxin-3 is not involved in binding
or activation of RXFP3, and its role is to provide a scaffold for
maintaining the helical structure within the B-chain.Mutagen-
esis studies of the B-chain in relaxin-3 led to the identification
of the key amino acid residues for receptor binding on the
B-chain central  helix (ArgB12, IleB15, ArgB16, IleB19, and
PheB20), whereas the amino acid residues ArgB26 and TrpB27 at
the C terminus make only a minor contribution to binding
affinity but are essential for receptor activation (Fig. 1,A and B)
(31).
Truncation of the C terminus of the B-chain led to the gen-
eration of an RXFP3 antagonist. Interestingly, the addition of a
non-native arginine after CysB22 at the C terminus, as a result of
an artifact of the recombinant production and processing, in
the peptide R3(B23–27)R/I5 increased the affinity for RXFP3
(31). A further study showed that the additional arginine is a
major contributor for the high-affinity binding of R3(B23–
27)R/I5 to RXFP3 (32). The introduction of this amino acid
residue has been suggested to provide an additional binding
interaction that compensates for the reduction in affinity from
the loss of the C-terminal amino acid residues (32). Subse-
quently, a single-chain variant of this truncated peptide with
the cysteine residues mutated to serine was developed. This
variant, R3 B1–22R (Fig. 1C), is also a high-affinity RXFP3
antagonist and, furthermore, does not have any affinity for the
RXFP4 or RXFP1 receptors and thus is RXFP3-specific (33).
Importantly, this peptide is unstructured in solution, and the
Arg23 residue is important for the high-affinity binding, as the
variant lacking this arginine demonstrated no binding to
RXFP3 (33).
Knowledge of the precise agonist and antagonist binding
sites on RXFP3 would further assist the structure-based design
of drug leads. Despite having a good understanding of the
important B-chain amino acid residues that are responsible for
the activity of relaxin-3, little is known about the amino acid
residues in RXFP3 that they are interacting with. Mutagenesis
studies on RXFP3 together withmolecularmodeling and ligand
docking demonstrated that ArgB12 and ArgB16 are likely inter-
acting with Glu244 in extracellular loop 2 (EL2) and Asp145 in
EL1, respectively, whereas ArgB26, one of the critical amino
acid residues for activating the receptor, is interacting with
Glu141 in transmembrane domain 2 (TM2) (Fig. 2A) (34, 35).
However, the interaction sites for the hydrophobic amino
acid residues, IleB15, IleB19, PheB20, and TrpB27, with the
receptor are still unknown. A further study using RXFP3
mutagenesis hypothesized that TrpB27 interacts with Trp138
in RXFP3 after a conformational change of the C terminus of
the peptide upon binding the receptor (36). Importantly,
there is no information as to the amino acid residues that
bind the RXFP3-specific antagonist R3 B1–22R, particularly
the non-native arginine Arg23 on its C terminus, which is the
largest contributor to its affinity. Given the prominent neu-
rological effects following the activation and inhibition of
RXFP3 signaling in the brain, RXFP3 presents immense
potential as a drug target to treat neurological disorders.
Designing small, receptor-specific drugs that can penetrate
the blood–brain barrier is challenging and requires under-
standing of the molecular details of the ligand–receptor
complex and the conformational changes that occur upon
activation. In the present study, we investigated the roles of
several amino acid residues in RXFP3 that we predicted
might be interacting with relaxin-3 and the R3 B1–22R sin-
gle-chain antagonist. Using site-directed mutagenesis, we
studied the effects of mutating these amino acid residues on
both agonist and antagonist binding as well as the effects of
mutations on the activation of RXFP3 following agonist
stimulation. Based on these data, we present detailed models
of the agonist and antagonist binding sites of RXFP3 and new
mechanistic insights into its function.
Figure 1. A, NMR solution structure of relaxin-3 (PDB entry 2FHW). The key
amino acid residues (shown as sticks) involved in binding are shown in cyan,
and those involved in activation are shown in red. Relaxin-3 A-chain is colored
inwheat, whereas the B-chain is colored in green. The C terminus of the relax-
in-3 B-chain folds back to interact with the -helical core residues. B, peptide
sequence of human relaxin-3 with the amino acid residues important for
binding highlighted in cyan, residues involved in activation highlighted in red,
and the cysteine residues forming disulfide bonds highlighted in yellow. C,
peptide sequence of R3 B1–22R with the binding residues utilized by relax-
in-3 highlighted in cyan, whereas Arg23, highlighted in magenta, is a non-na-
tive residue shown to be very important for binding to RXFP3.
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Results and discussion
Predictions of relaxin-3/RXFP3 interactions
In previous studies exploring the role of acidic amino acid
residues in RXFP3 for relaxin-3 binding, interaction partners
for the key basic amino acid residues in relaxin-3, ArgB12,
ArgB16, and ArgB26, were identified (34, 35) (Fig. 2A). These
interactions suggest that the relaxin-3 B-chain C terminus
inserts into the RXFP3 binding pocket, whereas the B-chain
helical region primarily packs against EL2. To further confirm
and refine the model of ligand binding and to also identify
hydrophobic amino acid residues in RXFP3 that are interacting
with the remaining amino acid residues critical for bioactivity
(IleB15, IleB19, PheB20, and TrpB27), we designed a new set of
rationally predicted RXFP3mutations based on the proximities
of ligand to receptor residues generated fromour docking stud-
ies of relaxin-3 on the RXFP3 homologymodel (Fig. 2B) that we
created in our previous study (34). Based on the model, IleB15
and IleB19 are exposed on a surface of the B-chain helix adjacent
to an RXFP3 hydrophobic patch that includes Val239, Val241,
Leu246, and Leu248 in EL2; thus, these were mutated to alanine
(Fig. 2B). PheB20 is exposed on a different face of the helix and is
observed to be in close proximity to another bulky residue on
TM7, Phe364, which was therefore also mutated to alanine (Fig.
2B). Finally, the C terminus of the B-chain is rather flexible, and
a conformational change has been suggested (35), meaning
there are a number of potential interaction partners for TrpB27,
including Trp138 in TM2; Thr162 and Met166 in TM3; His268
and Lys271 in TM5; Trp339, Thr346, Ser349, and Lys353 in TM6;
and Phe371 in TM7 (Fig. 2B). These amino acid residues were
also all individually mutated to alanine. The combination of
these mutations represents an extensive exploration of a large
portion of the RXFP3 ligand-binding pocket (Fig. 2B).
Effect of mutagenesis on agonist binding to RXFP3
A total of 15 mutations were generated based on their prox-
imity to key relaxin-3–binding residues. Themutantswere first
tested for changes in agonist binding in cell-based binding
assays using europium-labeled (Eu-)R3/I5. Receptor mutants
were tested in parallel for their cell surface expression, and the
final specific binding data were expressed as a ratio of the per-
centage of specific binding/cell surface expression. Eight of 15
mutations tested (W138A (TM2); T162A (TM3); V241A,
L246A, and L248A (EL2); K271A (TM5); and F364A and F371A
(TM7)) resulted in a significant loss (70–85% compared with
WT) in Eu-R3/I5–specific binding without affecting receptor
cell surface expression (Fig. 3 and Table 1). Other mutations,
such as V239A (EL2), W339A, T346A, S349A, and K353A
(TM6) had no effect on binding or cell surface expression (Fig.
3 and Table 1). On the other hand, M166A (TM3) and H268A
(TM5) showed increased specific agonist binding despite hav-
ing normal cell surface expression (Fig. 3 and Table 1). The
mutation of the bulky side chains of histidine andmethionine to
alaninemay free up steric constraints in the binding pocket and
hence the observedhigher specific binding.Additionally,His268
is positioned one helix turn above Lys271, which showed
affected agonist binding, and hence the removal of the His268
side chain may open up the binding pocket.
Activation ofmutant RXFP3 receptors
RXFP3, when activated by agonists, couples to Gi/o proteins
to inhibit cAMP production. To assess the ability of themutant
receptors to signal, we therefore used a pCRE--gal reporter
gene assay, which is an indirect readout of cAMP activity and
has been extensively utilized to assess agonist activity at RXFP3
(33, 37). When the mutant receptors were tested in cAMP
activity assays, 9 of 15 mutations demonstrated significantly
reduced agonist potency (pEC50) compared with WT RXFP3
(Fig. 4 and Table 1). Notably, there were no changes in ligand-
activated efficacy for all of the mutations where a full-dose
response was demonstrated. For the mutants where there was
not a full-dose response (W138A, L248A, K271A, W339A, and
F371A), efficacy values at 1M agonist were shown, and poten-
cies were described as 6 (Table 1). Seven of the 9 mutations
(W138A, T162A, L246A, L248A, K271A, F364A, and F371A)
previously showed decreased specific binding (Fig. 4 (A and B),
Fig. S1, and Table 1). Mutations atW138A, K271A, F371A, and
L248Awere particularly detrimental for activation, resulting in
Figure 2. Rational predictions of RXFP3 mutations guided by our previ-
ous homology model generated based on the inactive structure of
CXCR4. A, model of the relaxin-3–RXFP3 complex showing the electrostatic
interactions between the positively charged arginines ArgB12, ArgB16, and
ArgB26 (labeled in red) of relaxin-3 B-chain (green) and the negatively charged
Glu244, Asp145, and Glu141, respectively. B, extracellular view of the homology
model of RXFP3–relaxin-3 complex with relaxin-3 removed to provide a
clearer view. Amino acid residues rationalized to be interactingwith relaxin-3
are shown in sticks and color-coded accordingly. Residues in TM2 and TM3 are
shown in blue and residues in EL2, TM5, TM6, and TM7 are shown in yellow,
purple, red, and pink, respectively.
Mechanism of agonist and antagonist interaction at RXFP3
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more than 1000-fold lower agonist potency comparedwithWT
RXFP3, which suggest that these amino acid residues may be
involved in agonist recognition (Fig. 4 (A and B), Fig. S1, and
Table 1). Interestingly,W339A andT346A, which did not show
any significant decrease in specific agonist binding, demon-
strated significant losses in cAMP activity, suggesting their
roles in stabilizing the active conformation instead of a direct
role in ligand recognition (Figs. 3A and 4B, Fig. S1, andTable 1).
In particular, W339A demonstrated minimal activity (30%
efficacy; Table 1) to agonist at concentrations up to 1 M, sug-
gesting that this amino acid residue is probably important for
stabilizing the active receptor conformation, and mutations to
alanine shift the receptor toward the inactive state. Indeed,
Trp339 orW6.48 (according to theBallesteros–Weinstein num-
bering scheme (38)), which is located on the CWXP motif that
is widely known as the “rotamer toggle switch,” is important for
activation (39, 40). Mutagenesis studies of W6.48 in A3 adeno-
sine receptor, GPR119, GPR39, NK1, and the 2-adrenergic
receptor demonstrated thatmutation of this amino acid residue
significantly affected agonist-induced receptor activation but
did not impair agonist affinity (41, 42). The other four muta-
tions (T162A, L246A, T346A, and F364A) had significantly
lower agonist potency but showed a less dramatic drop (Fig. 4B,
Fig. S1, and Table 1). In contrast, V241A, which had a dramatic
loss in specific agonist binding, did not show impairment in
cAMP signaling (Fig. 4A and Table 1).
Refinedmodel of the RXFP3–relaxin 3 complex
In our previous study (34), we generated a homology model
of RXFP3 and performed ligand-docking simulations guided by
our mutagenesis data based on the inactive structure of the
CXCR4 receptor (PDB entry 3OEO (43)). We have utilized this
model to predict further interaction sites and perform more
RXFP3 alaninemutations in this study. Recently, the active (44)
and inactive (45) structures of the angiotensin II receptor type I,
which shares higher homology with RXFP3, became available,
which allowed us to use these structures as templates for the
homology modeling of active and inactive RXFP3 models to
refine docking based on our current mutagenesis and peptide
SAR data (see companion paper (59)). Based on these results,
we further refined our model of how relaxin-3 binds and acti-
vates RXFP3 (Fig. 5A). The importance of Leu246 and Leu248
strongly supports a binding mode that places IleB15 and IleB19
packed against the small -sheet in EL2 with hydrophobic
Figure 3. A, Eu-R3/I5–specific binding to mutant RXFP3 receptors compared with HA-RXFP3. Data are expressed as a ratio of specific Eu-R3/I5 binding to the
cell surface expressionof each construct andnormalized toHA-RXFP3binding.B, cell surface expressionofHA-tagged receptors comparedwithWTHA-RXFP3.
Data are expressed asmean S.D. (error bars) of triplicatemeasurements fromat least three independent experiments (n 3–8; *,p 0.001; #,p 0.05 versus
HA-RXFP3).
Mechanism of agonist and antagonist interaction at RXFP3
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interactions between IleB15 and Leu246 and between IleB19 and
Leu248 (Fig. 5B). IleB15 has been shown to be critical for relax-
in-3 binding previously (31) with an alanine replacement of this
amino acid residue resulting in a dramatic loss of affinity for
RXFP3. Replacement of IleB19 with alanine only shows a mod-
erate drop in affinity, but replacement with a charged amino
acid residue (glutamic acid) is detrimental, confirming the
importance of a hydrophobic nature at this position (31). The
V239A replacement in RXFP3 was well tolerated, suggesting
that this amino acid residue is outside the binding site. V241A,
despite showing a significant drop in Eu-R3/I5 binding, did not
show impairment in signaling, suggesting that itmay onlymake
a minor contribution to binding affinity.
TrpB27was positioned in our preliminarymodel towardTM5
and TM6, based on the preferred conformation of this amino
acid residue in the relaxin-3 solutionNMR structure. However,
of the amino acid residues mutated in this region (Thr162,
His268, Lys271, Trp339, Thr346, Ser349, Lys353 and Phe371), only
Thr162, Lys271, and Phe371 were found to be important for
RXFP3 binding and activation. NMR studies on relaxin-3 pep-
tide have suggested a degree of flexibility afforded by the Gly–
Gly hinge between the binding and activation domains, and
such a rearrangement has previously been proposed to allow for
receptor activation, as mutation of the flexible Gly-Gly to Ala-Ta
b
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Figure 4. Characterization of mutant receptors in a pCRE--gal reporter
gene assay in transiently transfected HEK293T cells. A, representative
dose-response curves forW138A in TM2, amutation that disrupted signaling,
andV241A in EL2, amutation that did not affect signaling. All individual dose-
response curves of mutant RXFP3 receptors are shown in Fig. S2. B and C, the
pEC50 (B) and efficacy of the inhibition (C) of forskolin-stimulated cAMP accu-
mulation when stimulated with the RXFP3 full agonist, analogue 2, at the
HA-RXFP3 and mutant RXFP3 receptors. Data are expressed as mean S.D.
(error bars) of triplicatemeasurements fromat least three independent exper-
iments (n  3–9; *, p  0.001; #, p  0.05 compared with HA-RXFP3). pEC50
and efficacy values are summarized in Table 1.
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Ser resulted in a dramatic drop in relaxin-3 activation potency
(46). The strong dependence of Trp138 on binding instead sug-
gested that the TrpB27 aromatic ring in relaxin-3 is stacked
against TM2. This, in turn, places the TrpB27 C terminus in a
position to be able to form a salt bridge across the binding
pocket to the extended side chain of Lys271 (Fig. 5B), an inter-
action that would explain the importance of both Lys271 and a
free acid at the C terminus for maximal activity (47). At the
same time this work was undertaken, the TrpB27 interaction
with Trp138 on TM2 was also demonstrated by Hu et al. (36),
showing that the mutant W138A was not able to discriminate
between relaxin-3 and a variant lacking TrpB27. Considering
that the C terminus is flexible and TrpB27 is a large amino acid
residue, the effects of mutations to Thr162 and Phe371 in its
proximity are also likely a result of either direct interactions or
indirect local conformational changes that affect its binding
pocket (Fig. 5B).
In the model, PheB20 is located on the other face of the relax-
in-3 B-chain helix and thus does not appear to be able to inter-
act with EL2. Instead, we speculated that through a small rota-
tion, it could contact amino acid residues on the opposite side
of the binding site. It was previously shown that the replace-
ment of PheB20 with alanine showed only a moderate drop in
affinity, but a replacement with a charged arginine or a polar
group like serine resulted in a significant affinity drop, suggest-
ing that the nature of the PheB20 interactions is hydrophobic
(31). Indeed, when PheB20 was replacedwith a hydrophobic and
bulky tyrosine, the affinity of the peptide was rescued (31). A
mutation to Phe364 in TM7 was used to probe this possibility,
and the variant F364A showed reduced agonist binding and
RXFP3 activation; thus, we propose that it is interacting with
relaxin-3 PheB20 (Fig. 5B).
Effect of mutagenesis of acidic residues on antagonist binding
in RXFP3
Little is known about how the single-chain antagonist R3
B1–22R interacts with RXFP3. Given that all features of the
helical portion of the B-chain are retained, key amino acid res-
idues in this region might be involved in similar interactions as
in relaxin-3. However, unlike relaxin-3, R3 B1–22R lacks the
C-terminal ArgB26 and TrpB27 interaction sites but gains an
additional high-affinity binding site through the non-native
C-terminal Arg23. In addition, it is known that R3 B1–22R with
a C-terminal acid binds with lower affinity compared with a
C-terminal amide (33). On the other hand, for relaxin-3, a
B-chainC-terminal acid is required for high affinity and activity
(47). Therefore, we would predict that there are some distinct
differences in the bindingmode comparedwith relaxin-3 due to
the critical new interactions introduced by the non-native
Arg23 and theC-terminal amide (see companion paper (59)). As
the unstructured antagonistmust still partially rely on the bind-
ing amino acid residues of relaxin-3, we hypothesized that R3
B1–22R formed a helical structure upon the first contact with
the receptor, which is primarily driven by Arg23, subsequently
allowing other binding amino acid residues on the central
region of R3B1–22R to interactwithRXFP3.Given the involve-
ment of positively charged arginines in the ligand (see compan-
ion paper (59)), we first screened binding to acidic mutant
receptors to analyzewhether these are involved in similar inter-
actions as with relaxin-3.
All of the acidicmutant receptors except E245Ahave been pre-
viously shown not to affect receptor cell surface expression (34).
E245A,which is pointing away from the binding site in ourmodel,
has impaired cell surface expression (34) (40% of WT) but
importantly has unchanged affinity for R3 B1–22R (Fig. 6A) but
reducedmaximumbinding, asexpected (Fig.S2andTable1).Both
Figure 5. A, relaxin-3 docked into an active-state homology model of RXFP3
(gray) with amino acid residues predicted to be interacting shown as sticks. B,
close-up of the predicted interactions between hydrophobic residues IleB15
and IleB19 on relaxin-3 with Leu246 and Leu248 in EL2 of RXFP3, PheB20 with
Phe364 in TM7 of RXFP3 and TrpB27 of the flexible C terminus with several
amino acid residues in TM2 (Trp138), TM3 (Thr162), TM5 (Lys271), and TM7
(Phe371). Ligandand receptor amino acid residues involved in interactions are
labeled in red and black, respectively.
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E244AandD145A,however,demonstrated reducedaffinity forR3
B1–22R(Fig. 6 (AandB), Fig. S2, andTable1), consistentwith our
hypothesis that they, as in relaxin-3, interact with Arg12 and
Arg16. R3 B1–22R lacks the C terminus of relaxin-3, but we
predicted that if both the agonist and the antagonist interact
with RXFP3 using similar residues, this would mean that R3
B1–22RArg23 could bind close to the amino acid residues inter-
acting with ArgB26 and TrpB27 of the agonist. Interestingly,
E141A also demonstrated reduced affinity for R3 B1–22R (Fig.
6B and Table 1), although its interaction partner ArgB26 of
relaxin-3 is missing in R3 B1–22R. Additionally, the combina-
tion of E141A/D145A further decreased the affinity (Fig. 6B and
Table 1). Notably, the double mutant was still able to bind R3
B1–22R, but we were not able to obtain an affinity that was
100 nM. Thus, Arg23 could potentially be interacting with
Glu141. However, as the removal of Arg23 from the R3 B1–22R
completely abolishes binding of the antagonist peptide, we
would have anticipated a complete loss of binding if its binding
partnerwas removed from the receptor.Hence, at this point, we
hypothesize that Glu141 is most likely not the only amino acid
residue that is interacting with Arg23.
Effect of mutagenesis of nonacidic residues on antagonist
binding in RXFP3
Given the involvement of Glu244 and Asp145, we predicted
that the hydrophobic patch on EL2 of RXFP3 could also retain
interactions with Ile15 and Ile19 of R3 B1–22R, as for relaxin-3.
To test this and further characterize the binding mode, we
tested all of the nonacidic mutant receptors for antagonist
binding. W138A, V241A, L246A, L248A, K271A, and F364A,
which affected agonist binding, also significantly decreased the
R3 B1–22R binding, albeit to a lesser extent than agonist bind-
ing (Fig. 6C and Table 1). Because we observed more subtle
changes in specific binding, we performed full saturation bind-
ing on these mutant receptors. W138A showed a pronounced
loss in binding affinity characterized in Eu-R3 B1–22R satura-
tion binding (Fig. 6D). L246A, L248A, K271A, and F364A had a
moderate (2-fold) but significant decrease in Kd (Fig. S2 and
Table 1), whereas V241A did not show any perturbations in
binding R3 B1–22 R as compared with WT (Fig. S2 and Table
1). H268A, T346A, and S349A resulted in a decrease in antag-
onist affinity (2–3-fold) but not agonist binding or potency,
suggesting that these amino acid residues are specifically inter-
acting only with the antagonist (Fig. 6C, Fig. S2, and Table 1).
On the other hand, K271A, which demonstrated decreased
agonist binding and potency, did not significantly impair
antagonist binding (Fig. S2 and Table 1). Although K271A
showed slightly reduced (75% of WT binding) antagonist
binding, this was not significantly different compared with
WT (p 0.05). However, saturation binding on K271A indi-
cated a slight reduction in antagonist affinity (Fig. S2 and
Table 1). There was no change in Bmax value for any mutant
receptor other than E245A, which also showed lower cell
surface binding. Taken together, this suggests that although
there are overlapping binding sites common to both antag-
onist and the agonist, there are also distinct differences in
the binding mode.
Despite the mutational data giving clear insights into the
antagonist interaction, these mutations so far had not resulted
in a complete loss of R3 B1–22R binding, which would be
expected if the amino acid residues interacting with Arg23 on
the antagonist had been eliminated. The most plausible expla-
nation is that Arg23 forms complex interactions with several
amino acid residues in the binding pocket, and hence, mutating
a single amino acid residue does not result in a complete loss
of binding. Analyzing the structural model, we predicted
that Arg23 could be forming both an ionic interaction with
Glu141 and a cation– interaction with Trp138. Thus, we
made the doubly mutated W138A/E141A. The W138A/
E141A mutant receptor was expressed normally at the cell
surface (Fig. 7A), but when tested in saturation binding, it
resulted in a complete loss of Eu-R3 B1–22R binding (Fig.
7B), strongly suggesting that our hypothesized interaction
with Arg23 is correct and explaining the absolute require-
ment of this amino acid residue.
Distinct but overlapping bindingmodes of agonist and
antagonist
Based on the mutagenesis data and our refined active- and
inactive-state RXFP3 models, we performed docking simula-
tions with the agonist and the antagonist to the active and inac-
tive RXFP3 models, respectively. Our data suggest distinct but
overlapping binding modes of relaxin-3 (Fig. 5A) and R3
B1–22R (Fig. 8A). AlthoughR3B1–22R is unstructured in solu-
tion, it likely forms a helix upon the interaction with RXFP3,
which ismainly driven by the high-affinity binding of Arg23 (see
companion paper (59)). It is not uncommon for intrinsically
disordered peptides that are flexible in solution to switch to a
well-ordered structure upon binding to its receptor. From pre-
vious structure–activity relationship studies (31, 33), it is
known that relaxin-3 utilizes binding amino acid residues on
the central helix of the B-chain, such as ArgB12, IleB15, ArgB16,
and IleB19. In our refined models guided by mutagenesis, we
postulate that these amino acid residues in both relaxin-3 and
R3 B1–22R interact with amino acid residues Glu244, Leu246,
Asp145, and Leu248, respectively, forming a binding surface
spanning extracellular loops 1 and 2 (Figs. 5B and 8A).
For relaxin-3, the C-terminal tail with the critical ArgB26-
TrpB27 inserts into the binding pocket to activate the receptor.
ArgB26 forms a previously identified key ionic interaction with
Glu141. TrpB27 at the C terminus is a large amino acid residue,
and the flexibility imparted by the Gly–Gly hinge makes pre-
dictions of its exact position and multiple interaction partners
difficult. However, we have refined our models, and based on
functional assays, we hypothesized that TrpB27 stacks onTrp138
of TM2. This is consistent with a previous study that identified
Trp138 as key amino acid residue interacting with TrpB27 of
relaxin-3, as the removal of TrpB27 renders relaxin-3 insensitive
to the alanine mutationW138A (36). Importantly, this confor-
mational rearrangement allows the backbone carboxyl of
TrpB27 to interact with Lys271 on the other side of the binding
site, on TM5 (Fig. 5B). The importance of both Lys271 and the
free acid at the C terminus can thus potentially be explained by
a salt bridge between these oppositely charged groups. Finally,
we proposed that PheB20 stretches across the top of RXFP3 to
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form an interaction with Phe364. Thus, the large relaxin-3 pep-
tide covers the majority of the extracellular parts of the recep-
tor, essentially forming a lid over the binding pocket, which
accommodates the activation domain.
For R3 B1–22R, nothing was previously known about how
the non-native Arg23 interacted with RXFP3 to maintain
RXFP3 in an inactive state. Given that Arg23 is positively
charged, we expected to easily identify a counterpart negatively
Figure 6.A, specific Eu-R3 B1–22Rbinding to RXFP3 receptorswithmutations in residues predicted to be involved in electrostatic interactionswith R3 B1–22R.
B, representative Eu-R3B1–22R saturationbinding curves fit to one-site specific bindingof acidicmutants E141AandD145Aanddoublemutant E141A/D145A.
All saturation binding curves for mutant receptors are shown in Fig. S2. C, specific Eu-R3 B1–22R binding to hydrophobic residue mutant RXFP3 receptors
predicted to form hydrophobic interactions with R3 B1–22R.D, saturation binding of Eu-R3 B1–22R to hydrophobicW138Amutant receptor fitted to one-site
specific binding. Data are expressed asmean S.E. (error bars) of triplicatemeasurements fromat least three independent experiments (n 3–19; *,p 0.001;
#, p 0.05 compared with HA RXFP3). Kd values of mutant receptors are summarized in Table 1.
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charged amino acid residue in RXFP3 as the key binding part-
ner.However, no single acid residuemutation resulted in a total
binding loss. Thus, we predicted that Arg23 is making interac-
tionswith several amino acid residues, andwith the guide of the
inactive-state RXFP3 model and ligand docking, we postulate
the binding site of Arg23 to be sandwiched between Trp138 and
Glu141 in TM2, forming both ionic and cation– type inter-
actions (Fig. 8B).
In relaxin-3, the B-chain helix ending at Cys22 and the acti-
vation domain ArgB26-TrpB27 are separated by a short linker
sequence, Gly-Gly-Ser. In contrast, in the antagonist, Arg23 fol-
lows directly on the putative helical segment, which has several
consequences for the binding. First, for the Arg23 to reach into
the binding pocket, the helix likely sits deeper in the transmem-
brane domains of RXFP3, which is possible for the smaller pep-
tide lacking the A-chain. A few amino acid residues in TM5
(His268) andTM6 (Thr346 and Ser349) affected R3B1–22R bind-
ing but not relaxin-3 binding, which may be a result of this
difference in positioning (Fig. 8). R3 B1–22R is a more potent
antagonist as a peptide amide, with R3 B1–22R acid having a
10-fold lower affinity for RXFP3 (33). This is in contrast to
relaxin-3, where the acid is favored. This can be explained by
the fact that in relaxin-3, the longer tail allows the acid to poten-
tially interact with Lys271; however, in the shorter tail of the
antagonist, this interaction is not possible. Thus, the amide
form, which does not require burying a charge that’s not
involved in an ionic interaction, is favored.
In summary, our current mutagenesis studies have led to
refined models of relaxin-3 bound to an active-state model and
R3 B1–22R bound to an inactive-state model of RXFP3 with
improved accuracy and reliability. These data together with
extensive mutagenesis data on R3 B1–22R in the companion
article (59) have significantly improved our understanding of
how relaxin-3 and R3 B1–22R interact with RXFP3. Such
information is extremely valuable for structure-based drug
design efforts to design next-generation RXFP3 agonists and
antagonists.
Experimental procedures
Reagents
The RXFP3 full agonist analogue 2 and the antagonist R3
B1–22R were chemically prepared as described previously (33,
37). Eu-R3/I5, Eu-R3/I5, andEu-labeledR3B1–22R, Eu-H3B1–
22R, were prepared as described previously (37, 48). Synthetic
oligonucleotides were purchased from Sigma-Aldrich and are
listed in Table S1. PCRs and cloning were undertaken as
described previously (34). Delfia Enhancement Solution was
purchased from PerkinElmer Life Sciences.
Mammalian cell culture
Human embyronic kidney 293T (HEK293T) cells (ATCC
catalogue no. CRL-1573) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Gibco) supplemented
with 10% fetal bovine serum (HyClone), 1% L-glutamine
Figure 7. A, cell surface expression of double mutant W138A/E141A showing that the double mutant receptor is expressed at the same level as HA-RXFP3. B,
saturation binding of Eu-R3 B1–22R on doublemutantW138A/E141A demonstrates a complete loss of antagonist binding. Data are expressed asmean S.E.
(error bars) of triplicate measurements from at least three independent experiments.
Figure 8. Antagonist R3 B1–22R binding site. A, an inactive-state homo-
logymodel of RXFP3 docked with R3 B1–22R. R3 B1–22R is predicted to form
a helix upon Arg23 binding to RXFP3, allowing other binding amino acid res-
idues to interact with counterpart amino acid residues in RXFP3. RXFP3 is
colored ingray, with amino acid residues interactingwith R3B1–22R shown in
sticks and labeled in black. Amino acid residues on R3 B1–22R involved in
binding are shown in sticks and labeled in red. B, close-up interactions of Arg23
with Glu141 and Trp138 on RXFP3, with Arg23 sandwiched betweenGlu141 and
Trp138 to form electrostatic and cation– interactions with Glu141 and Trp138,
respectively.
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(Gibco), and 1% penicillin/streptomycin (Gibco) in incuba-
tors at 37 °C, 5% CO2, and 85% humidity. HEK293T cells
were transfected with Lipofectamine2000 (Thermo Fisher
Scientific).
Site-directedmutagenesis
The forward and reverse primers for all mutants were
designed with partially overlapping ends as described (49) and
are listed in Table S1. Mutagenesis reactions on pcDNA3.1zeo
() HA RXFP3 were performed using the method described
previously (34). Individual mutants were screened and con-
firmed by DNA sequencing on both strands (Centre of Trans-
lational Pathology, University of Melbourne) to ensure that
there were no introduced random mutations.
Homologymodeling and docking
A model of RXFP3 with relaxin-3 docked into the binding
site was prepared as described earlier (34) but using a different
template for homology modeling. Briefly, the NMR solution
structure of relaxin-3 (PDB entry 2FHW (28)) was used
together with a homology model of RXFP3 based on the crystal
structure of angiotensin II receptor in an activated state (PDB
entry 5XJM (44)). Distance restraints corresponding to muta-
tional data were introduced during the homology modeling
procedure in Modeler 9v18 (50) to create an initial docking
pose of relaxin-3 on RXFP3. The model was then embedded in
a POPC/POPE/cholesterol membrane (60:20:20 relative com-
position) of dimensions 1.7	 1.7 nm using the insane.py script
(51) and the coarse-grained force field Martini version 2.0 (52).
The system was then simulated for 500 ns to equilibrate the
membrane using the Gromacs 2018.2 molecular dynamics
engine (53). The system was then converted back to all-atom
representation using an in-house modified version of the Back-
ward algorithm (54). The system was then minimized and then
equilibrated over 5 ns using the amber lipid17 and ff14SB force
fields (55) and the molecular dynamics engine Amber18 (56).
During the equilibration, the system was progressively heated
up to 300 K with the protein heavy atoms restrained to their
initial coordinates during the first 2.5 ns, and these restraints
were then progressively removed over a 2.5-ns simulation time.
The system was then simulated for 20 ns without restraints.
The Langevin theromostat with a damping coefficient of 2.0
ps
1 and the Berendsen barostat with a coupling time constant
of 1.0 pswere used tomaintain pressure and temperature at 300
K and 1.0 bar, respectively. The root mean square deviation of
the protein heavy atom coordinates to their initial position sta-
bilized at 2.2 Å after a 4-ns simulation, suggesting that the sys-
tem reached equilibrium.
A model of the antagonist bound to RXFP3 was generated
similarly but using as a template for the receptor the X-ray
structure of angiotensin I in an inactive state (PDB entry 4YAY
(45)). The initial position of the antagonist was modeled man-
uallywith PyMOLversion 2.0 (Schrödinger, LLC,NewYork) by
considering the RXFP3/relaxin-3 binding mode, deleting the
A-chain of relaxin-3, and repositioning the B-chain deeper in
the binding pocket to satisfy the experimental data on theArg23
positioning. This model was then embedded in a membrane
and refined using molecular dynamics simulation similarly as
the RXFP3/relaxin-3model. The rootmean square deviation of
the protein heavy atom coordinates to their initial position sta-
bilized at 2.9 Å after a 12-ns simulation, suggesting that the
system reached equilibrium.
The final frames of the RXFP3/relaxin-3 and RXFP3/antag-
onist simulations were energy-minimized and used for inter-
preting mutational data. The resulting molecular models of the
complexes have MolProbity scores (57) of 1.5 and 1.3, corre-
sponding to the 96th and 98th percentile (100th percentile is
the best), suggesting that the geometry of the models is
excellent.
Agonist and antagonist whole-cell binding assays
HEK293T cells were plated out at 25,000 cells/well and were
transfected in a 96-well ViewPlate (PerkinElmer Life Sciences)
with plasmids encoding the constructs of interest (250 ng/well)
and Eu-H3/I5 and Eu-R3 B1–22R binding assays conducted as
described previously (34, 37, 48). Specific binding screening
assays were performed using 5 nM Eu-R3/I5 in agonist-binding
assays or 5 nM Eu-R3 B1–22R in antagonist-binding assays in
the absence (total binding) and presence (nonspecific binding)
of 1 M unlabeled R3 B1–22R as described previously (34). Sat-
uration binding assays were performed by preparing different
concentrations of Eu-R3 B1–22R with (nonspecific binding)
and without (total binding) competition of 1 M unlabeled R3
B1–22R in 1% BSA in relaxin receptor binding buffer (20 mM
HEPES, pH 7.5, 1.5 mM CaCl2, 50 mM NaCl). Ligands were
incubated for 90 min at room temperature and were then aspi-
rated and washed with 200 l/well cold PBS. 100 l of Delfia
Enhancement Solution was then added to each well, and the
plate was shaken at 500 rpm for 15 min. The time-resolved
fluorescence of europium was read on an Omega POLARstar
(BMG Labtech) with the excitation/emission settings of 340
nm/615 nm. Specific binding was determined by subtracting
the nonspecific binding from the total binding, and the graph
was fitted to a one-site specific binding nonlinear regression.
Each concentration point was performed in triplicate, and data
were expressed as mean S.D. from at least three independent
experiments. Significance was assessed using one-way analysis
of variance (ANOVA) with Fisher’s least significant difference
(LSD) test onGraphPad Prism version 7.0 (GraphPad Software,
La Jolla, CA).
Cell surface expression assays
All receptor constructs were expressed with a hemagglutinin
(HA) epitope tag on theN terminus.HEK293T cellswere plated
at 200,000 cells/ml of DMEM in a 24-well plate (Costar) pre-
coated with poly-L-lysine and transfected with 1 g of plasmid
DNA/well for 24 h as described previously (34). 24 h later, the
mediawere aspirated, and cells werewashedwithTris-buffered
saline (TBS) solution (50 mM Tris, pH 7.4, 150 mMNaCl). Cells
were then fixed with 3.7% formaldehyde in TBS for 20 min at
room temperature, followed by two washes with TBS and sub-
sequently blocked with 1% BSA/TBS for 30 min. The HA
epitope tag was detected using a purified mouse monoclonal
anti-HA, HA.11(16B12) (Covance), made up in a 1:1000 dilu-
tion in 1% BSA/TBS (400 l/well) for 2 h at room temperature.
The cells were washed and incubated with a 1:1000 dilution of
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Alexa 488–conjugated goat anti-mouse IgG made up in 1%
BSA/TBS (400 l/well). Cells were then washed two times; 200
l of lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 0.25% Triton X-100) was added to each well; and the
plate was shaken for 15 min at 300 r.p.m. at room temperature.
Cell lysates were then scraped, and 180 l of cell lysates were
transferred to a 96-well black Optiplate (Costar) to be read
on Omega POLARstar (BMG Labtech) with excitation/emis-
sion wavelength of 490 nm/520 nm. Cell surface expression
was determined by subtracting nonspecific binding of the
antibody in cells transfected with pcDNA3.1 () zeo and
divided by the HA-RXFP3 WT expression to get a percent-
age HA-RXFP3 expression. Significance was assessed using
one-way ANOVA with Fisher’s LSD test on GraphPad Prism
version 7.0.
cAMP activity assays
HEK293T cells were plated at 25,000 cells/well in a 96-well
CellBind plate (Corning) and co-transfected the next day with
plasmid encoding various RXFP3 receptor constructs and
pCRE -gal as a cAMP-response element (CRE)-controlled
reporter of cAMP activity (58). 24 h post-transfection, medium
was removed, and increasing concentrations of the RXFP3 full
agonist, analogue 2 (37), made up in DMEM containing 500 nM
forskolin were added to the respective wells. The stimulation
was carried out for 6 h at 37 °C, 5% CO2, after which medium
was aspirated and plates were kept frozen at 
80 °C until fur-
ther analysis. Development of the plates required the plates and
assay buffers to be first thawed to room temperature. 25 l of
assay buffer 1 (100mMNa2HPO4, pH 8.0, 2mMMgSO4, and 0.1
mMMnCl2) was added into each well and shaken at room tem-
perature for 10min before adding 100l of assay buffer 2 (sim-
ilar to buffer 1 with the addition of 0.5% Triton X-100 and 40
mM -mercaptoethanol) into each well and further shaken for
10 min at room temperature. 25 l of substrate for -gal, chlo-
rophenol red -D-galactopyranoside (Roche Applied Science),
was added into each well with shaking until color change was
observed. The plate was then read and absorbance was mea-
sured at 570 nm on a Bio-Rad plate reader. Readings were nor-
malized to medium containing 500 nM forskolin (positive con-
trol) as 100% and to medium only (negative control) as 0%.
Normalized datawere fitted to a nonlinear regression sigmoidal
dose-response curve onGraphPad Prism version 6.0. Each con-
centration pointwas performed in triplicates, and the datawere
expressed as mean  S.E. from at least three independent
experiments. pEC50 values of each mutant construct were sub-
jected to one-way ANOVAwith Fisher’s LSD test onGraphPad
Prism version 7.0.
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